PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population

The molecular therapy of colorectal cancer

(2010) Maximilian J. Waldner et al.   MOLECULAR ASPECTS OF MEDICINE

Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer

(2009) Anna Isinger Ekstrand et al.   Familial Cancer

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

(2009) Pierre Laurent-Puig et al.   JOURNAL OF CLINICAL ONCOLOGY

PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer

(2009) Shuji Ogino et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

(2008) F. Perrone et al.   ANNALS OF ONCOLOGY

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Multiplexed Assays for Detection of Mutations in PIK3CA

(2008) R. E. Board et al.   CLINICAL CHEMISTRY

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY